Home Sleep Testing (HST), Obstructive Sleep Apnea

Navigating Insurance and Reimbursement

Insurance coverage and reimbursement for home sleep testing (HST) devices have improved in leaps and bounds over the last two decades, but unfortunately, denials and delays in care remain far too common. 

For many providers, figuring out a way forward can feel like navigating a labyrinth of policies and red tape. At iSleep Physicians, we’ve found that a proactive and multifaceted approach can help cut down on the confusion.

This article will highlight some of the most common hurdles in insurance, coding, and reimbursement for HST and offer practical strategies for moving forward when it feels like you’ve hit a wall.

By facing barriers head-on, we as sleep professionals can continue to expand access to life-changing diagnostic tools and improve outcomes for patients with sleep disorders.

THE OBSTACLE

Inconsistencies in Insurance Coverage

Insurance coverage for HST devices varies widely depending on the payer, state policies, and the specifics of the patient’s condition. Medicare, for instance, offers coverage for HST when it is used to diagnose obstructive sleep apnea (OSA) in patients meeting specific criteria, such as moderate to high pre-test probability of OSA. Private insurers often follow similar guidelines but may have additional requirements, such as prior authorization.

HOW TO MOVE FORWARD

Understand individual payer policies

Regularly review payer updates and maintain a database of coverage requirements for common insurers.

Document, document, document.

Ensure that patient records include comprehensive evidence supporting the need for HST, such as clinical notes, risk factor assessments, and Epworth Sleepiness Scale scores.

THE OBSTACLE

Prior Authorization Pitfalls

Many insurers require prior authorization for HST devices, adding an administrative hurdle for providers. The approval process often involves submitting detailed patient information, including clinical justification for the test. Delays in authorization can impact patient care, leading to frustration for both patients and providers.

HOW TO MOVE FORWARD

Establish dedicated workflows

Assign staff to handle authorizations and ensure timely submissions, incorporating automation when possible.

Leverage targeted technology

Utilize online portals or mobile apps offered by insurers to expedite the approval process.

THE OBSTACLE

Coding Conundrums 

Coding is critical in securing reimbursement. Many sleep centers face issues with denials due to incorrect coding.

Common pitfalls include using outdated codes, failing to match codes with payer-specific requirements, or omitting modifiers. The most common CPT codes for HST include:

  • 95800: Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (e.g., by airflow or peripheral arterial tone), and sleep time.
  • 95806: Sleep study, unattended, simultaneous recording of, heart rate, oxygen saturation, respiratory airflow, and respiratory effort (e.g., thoracoabdominal movement). Often used for type III HST devices.
  • G0399: Home sleep test (HST) with type III portable monitor; unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ECG/heart rate, and 1 oxygen saturation. Often used with Medicare-specific claims.

HOW TO MOVE FORWARD

Invest in staff training

Ensure that your billing team is well-versed in coding nuances.

Utilize software solutions

Modern electronic health record (EHR) systems can help flag discrepancies in real time.

THE OBSTACLE

Disparities in Reimbursement Rates and Disparities

Reimbursement rates for HST are generally lower than those for in-lab polysomnography (PSG). While this aligns with the lower operational costs of HST, the gap can strain small sleep centers that rely heavily on diagnostic services. Additionally, there is significant variability in rates among payers. For instance, Medicare reimbursement may differ substantially from private insurers, creating a financial challenge for sleep practices.

HOW TO MOVE FORWARD

Negotiate with insurers

Engage in contract renegotiations to advocate for fair reimbursement rates that reflect the value of HST in reducing health care costs through early diagnosis.

Track denied claims

Regular analysis of denied claims can help identify patterns and adjust billing practices accordingly.

THE OBSTACLE

Financial Barriers for Patients

Even when insurance covers HST, high deductibles, co-pays, and out-of-pocket costs can deter patients from proceeding with the test. This is particularly true for underinsured or uninsured populations.

HOW TO MOVE FORWARD

Discuss financial options upfront

 Transparency about costs can help patients make informed decisions.

Explore alternative funding

Partner with organizations or offer payment plans to reduce the financial burden on patients.

Charting a New Course

The challenges outlined above are more than just administrative headaches—they point to deeper issues that underscore the need for systemic changes in how insurance policies and reimbursement rates address HST. While sleep professionals can take steps to improve internal processes, true progress will require broader policy reform.

Advocacy from professional organizations like the American Academy of Sleep Medicine (AASM) plays a vital role in this effort. Among the most pressing needs are

standardizing coverage criteria across payers and pushing for fair reimbursement rates that reflect the clinical value of HST.

Coordinated advocacy and continued engagement with policymakers will be essential to chart a new course with consistency in coverage and reimbursement.

By Haramandeep Singh, MD, D. ABPN

Source: SleepWorld Magazine May/June 2025

Board Certified Sleep Medicine & Psychiatry

Haramandeep Singh, MD, is a board-certified sleep physician and chief executive officer of iSleep Physicians, which offers sleep interpretation and telemedicine in all 50 states for both pediatric and adult patients.

Disclosure: Speaker consultant for Jazz Pharmaceuticals, Axsome Therapeutics, Avadel Pharmaceuticals, and Harmony Biosciences.

 

 

Leave a Reply